Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.57 |
| ▸ | TUBB | P07437 | 1/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.57 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.57 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857324 | 0.89 | AXL (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3885714 | 0.86 | CDC7 (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22802293 | 0.86 | AXL (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29286701 | 0.86 | AXL (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL7712274 | 0.86 | RHEB (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29286702 | 0.82 | IDO1 (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL856966 | 0.82 | AXL (0.49) | METAXLGPR84LRRK2KMT2A | |
| SCHEMBL28061033 | 0.79 | IDO1 (0.56) | MAP2K1DRD4 | |
| SCHEMBL11612594 | 0.77 | AXL (0.55) | METAXLGPR84LRRK2KMT2A | |
| SCHEMBL22330299 | 0.77 | AXL (0.55) | METAXLGPR84LRRK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-7057039-B2 | 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-06-06 | — | — | US | disclosed |
| CN-1668620-A | 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1551840-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| EP-1509522-A1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth, A Corporation of the State of Delaware (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6825212-B2 | SEROTONINE RECEPTORS ANTAGONIST; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20040023970-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
| WO-2004009600-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-25 | — | — | US | disclosed |
| WO-2003101990-A1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | TUBB4A 1164/4885TUBB 805/4885TUBA3C 662/4885 |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR3B | TUBB4A 1205/4885TUBB 841/4885TUBA3C 731/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | TUBB4A 1759/4885TUBB 1155/4885TUBA3C 2762/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | TUBB4A 1759/4885TUBB 1155/4885TUBA3C 2762/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | TUBB4A 1759/4885TUBB 1155/4885TUBA3C 2762/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | TUBB4A 1759/4885TUBB 1155/4885TUBA3C 2762/4885 |
| US-20040023970-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR5A | TUBB4A 2087/4885TUBB 1523/4885TUBA3C 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.